Skip to content
Taxol, Paxene(paclitaxel)
Abraxane, Apealea (paclitaxel) is a small molecule pharmaceutical. Paclitaxel was first approved as Taxol on 1992-12-29. It is used to treat breast neoplasms, kaposi sarcoma, non-small-cell lung carcinoma, and ovarian neoplasms in the USA. It has been approved in Europe to treat breast neoplasms, kaposi sarcoma, non-small-cell lung carcinoma, ovarian neoplasms, and pancreatic neoplasms. The pharmaceutical is active against tubulin beta chain. In addition, it is known to target nuclear receptor subfamily 1 group I member 2 and toll-like receptor 4.
Download report
Favorite
BMS
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
infectionsD007239
neoplasmsD009369
digestive system diseasesD004066
respiratory tract diseasesD012140
urogenital diseasesD000091642
skin and connective tissue diseasesD017437
endocrine system diseasesD004700
Trade Name
FDA
EMA
Abraxane (generic drugs available since 2002-01-25, discontinued: Taxol)
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Paclitaxel
Tradename
Company
Number
Date
Products
PACLITAXELAmerican RegentN-211875 RX2022-07-27
1 products, RLD, RS
ABRAXANEBristol Myers SquibbN-021660 RX2005-01-07
1 products, RLD, RS
PACLITAXELTEVA PHARMS INCN-216338 RX2023-05-11
1 products, RLD, RS
Show 1 discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
abraxaneNew Drug Application2020-09-03
paclitaxelNew Drug Application2023-05-04
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
breast neoplasmsEFO_0003869D001943C50
kaposi sarcomaD012514C46
non-small-cell lung carcinomaD002289
ovarian neoplasmsEFO_0003893D010051C56
Agency Specific
FDA
EMA
Expiration
Code
PACLITAXEL, ABRAXANE, BRISTOL-MYERS
2023-06-06PED
Patent Expiration
Patent
Expires
Flag
FDA Information
Paclitaxel, Abraxane, Bristol-Myers
95110462034-01-12U-1434
93933182032-03-04U-1290
95974092032-03-04U-1290
80343752026-08-13U-1290
77588912026-02-21U-1434
82683482026-02-21U-1290
91015432026-02-21U-1434
78207882024-10-27DPU-1092, U-1290, U-1434
79235362023-12-09U-1117, U-1290, U-1434
81382292023-12-09DPU-1092, U-1290, U-1434
83141562023-12-09U-1290, U-1434
ATC Codes
L: Antineoplastic and immunomodulating agents
L01: Antineoplastic agents
L01C: Plant alkaloids and other natural products, antineoplastic drugs
L01CD: Taxanes, antineoplastic
L01CD01: Paclitaxel
L01CD03: Paclitaxel poliglumex
HCPCS
Code
Description
J9264
Injection, paclitaxel protein-bound particles, 1 mg
J9267
Injection, paclitaxel, 1 mg
S1016
Non-pvc (polyvinyl chloride) intravenous administration set, for use with drugs that are not stable in pvc e.g., paclitaxel
Clinical
Clinical Trials
3604 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Breast neoplasmsD001943EFO_0003869C501633971401640676
Non-small-cell lung carcinomaD002289112254121511455
Ovarian neoplasmsD010051EFO_0003893C561051727118319
NeoplasmsD009369C8025488934299
Pancreatic neoplasmsD010190EFO_0003860C2513418219314291
Lung neoplasmsD008175C34.90421134817188
Squamous cell carcinoma of head and neckD000077195215562176
Coronary artery diseaseD003324I25.1918202365
AdenocarcinomaD000230194291461
Pancreatic ductal carcinomaD021441243371254
Show 22 more
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Triple negative breast neoplasmsD06472645100301147
Fallopian tube neoplasmsD0051855272392147
Stomach neoplasmsD013274EFO_0003897C164596216140
Esophageal neoplasmsD004938C152780275123
Uterine cervical neoplasmsD002583144129583
Head and neck neoplasmsD00625824569281
Esophageal squamous cell carcinomaD000077277105317273
Endometrial neoplasmsD016889EFO_000423025341870
MelanomaD0085452337759
Ovarian epithelial carcinomaD000077216242510154
Show 100 more
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Colorectal neoplasmsD0151791816126
LymphomaD008223C85.914719
Liver neoplasmsD008113EFO_1001513C22.067112
Transitional cell carcinomaD00229511011
Uterine neoplasmsD014594EFO_0003859C5531111
Non-hodgkin lymphomaD008228C85.98310
CystadenocarcinomaD0035366410
Central nervous system neoplasmsD016543569
HemangiosarcomaD00639477
Thyroid neoplasmsD013964EFO_0003841356
Show 88 more
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hematologic neoplasmsD01933755
Hodgkin diseaseD006689C8144
Kidney diseasesD007674EFO_0003086N08123
Myelodysplastic syndromesD009190D4622
Myeloid leukemia acuteD015470C92.022
Precursor cell lymphoblastic leukemia-lymphomaD054198C91.022
Myelomonocytic leukemia chronicD015477C93.122
Rectal neoplasmsD01200422
Follicular lymphomaD008224C8222
Mucinous cystadenomaD018291112
Show 38 more
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic kidney failureD007676EFO_0003884N18.622
Type 2 diabetes mellitusD003924EFO_0001360E1111
MedulloblastomaD00852711
RetinoblastomaD01217511
Primitive neuroectodermal tumorsD01824211
HepatoblastomaD018197C22.211
Retinal neoplasmsD019572C69.211
PhenylketonuriasD010661E70.011
Breast diseasesD001941N60-N6511
StrokeD020521EFO_0000712I63.911
Show 12 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common namePACLITAXEL
INNpaclitaxel
Description
Paclitaxel is a tetracyclic diterpenoid isolated originally from the bark of the Pacific yew tree, Taxus brevifolia. It is a mitotic inhibitor used in cancer chemotherapy. Note that the use of the former generic name 'taxol' is now limited, as Taxol is a registered trade mark. It has a role as a microtubule-stabilising agent, a metabolite, a human metabolite and an antineoplastic agent. It is a tetracyclic diterpenoid and a taxane diterpenoid. It is functionally related to a baccatin III.
Classification
Small molecule
Drug classantineoplastics, taxane derivatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
CC(=O)O[C@H]1C(=O)[C@]2(C)[C@@H](O)C[C@H]3OC[C@@]3(OC(C)=O)[C@H]2[C@H](OC(=O)c2ccccc2)[C@]2(O)C[C@H](OC(=O)[C@H](O)[C@@H](NC(=O)c3ccccc3)c3ccccc3)C(C)=C1C2(C)C
Identifiers
PDB
CAS-ID33069-62-4
RxCUI56946
ChEMBL IDCHEMBL428647
ChEBI ID45863
PubChem CID36314
DrugBankDB01229
UNII IDP88XT4IS4D (ChemIDplus, GSRS)
Target
Agency Approved
TUBB
TUBB
Organism
Homo sapiens
Gene name
TUBB
Gene synonyms
TUBB5
NCBI Gene ID
Protein name
tubulin beta chain
Protein synonyms
beta Ib tubulin, epididymis secretory sperm binding protein, tubulin beta-1 chain, Tubulin beta-5 chain, tubulin, beta polypeptide
Uniprot ID
Mouse ortholog
Tubb5 (22154)
tubulin beta-5 chain (Q3UF52)
Alternate
NR1I2
NR1I2
TLR4
TLR4
Organism
Homo sapiens
Gene name
NR1I2
Gene synonyms
PXR
NCBI Gene ID
Protein name
nuclear receptor subfamily 1 group I member 2
Protein synonyms
Orphan nuclear receptor PAR1, Orphan nuclear receptor PXR, Pregnane X receptor, Steroid and xenobiotic receptor, SXR
Uniprot ID
Mouse ortholog
Nr1i2 (18171)
nuclear receptor subfamily 1 group I member 2 (O54915)
Variants
Clinical Variant
No data
Financial
Abraxane - Bristol Myers Squibb
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Abraxane - Celgene
$
£
Mock data
Subscribe for the real data
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 147,582 documents
View more details
Safety
Black-box Warning
Black-box warning for: Abraxane, Paclitaxel
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
1,680 adverse events reported
View more details